Related Experiment Video
Updated: Jul 16, 2026

Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol
Published on: July 28, 2018
High-Volume Hemofiltration: What Are the Last Indications in 2026? - A Narrative Review
Julien Moury1, Sebastien Redant2, Willem Boer3
1CHU UCL Namur Godinne, UCLouvain Medical School, Ottignies-Louvain-la-Neuve, Belgium.
Background:
High-dose continuous therapies and especially high-volume hemofiltration have failed to demonstrate clinical benefit in septic shock and are, therefore, no longer recommended in this setting. However, extrapolating this negative conclusion to all clinical indications may be inappropriate.
Summary:
This narrative review revisits the current and emerging indications for high-dose continuous therapies beyond sepsis, focusing on pathophysiological rationale and toxin kinetics. Recent evidence, notably the CONVINCE trial, has established high-volume intermittent post-dilution online hemodiafiltration as superior to conventional hemodialysis in chronic kidney disease, likely through enhanced removal of middle and protein-bound uremic toxins. In acute settings, high-dose continuous therapy strategies play a critical neuroprotective role in hyperammonemia - both hepatic and non-hepatic - as well as in selected severe drug intoxications, including valproate, metformin, and lithium.
Key Messages:
When appropriately selected and adequately dosed, high-dose continuous therapies remain powerful, targeted tools in modern blood purification.
Related Concept Videos
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Hemodialysis I: Introduction
Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Heart Failure VI: Adjunct Therapies